ReviewTherapeutic advances in infectious disease2016
Recent developments and future prospects in the treatment of visceral leishmaniasis.
Review in Therapeutic advances in infectious disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Plant-based therapeutics for leishmaniasis: A systematic review emphasizing human studies and clinical trial evidence.PLoS neglected tropical diseases · 2026Pooled it
- Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.Infectious diseases of poverty · 2018Pooled it
- Article
- The pharmaceutical industry's multifaceted role in neglected tropical disease control: from market failure to global health innovation.Tropical medicine and health · 2026Review
- Orphan Medications: An Innovative and Promising Approach against Leishmaniasis.Current microbiology · 2026Review
- Sand fly endosymbionts in Kenya: Rickettsia and Wolbachia associations with Leishmania and detection of Rickettsia africae.Parasites & vectors · 2026Article
- Retinoic acid-loaded nanoparticles enhance macrophage-mediated control ofTurkish journal of biology = Turk biyoloji dergisi · 2026Article
- A Forgotten Foe Returns: The Diagnostic Odyssey of Kala-Azar Masquerading as Myelodysplastic Syndrome in a Post-Elimination Era.Clinical case reports · 2025Article
- Navigating Diagnosis and Treatment Dilemmas in Visceral Leishmaniasis Reactivation in a HIV-Positive Patient.Cureus · 2024Article
- Article
- Therapeutic Activity of a Topical Formulation Containing 8-Hydroxyquinoline for Cutaneous Leishmaniasis.Pharmaceutics · 2023Article
- Incorporation ofInternational journal of molecular sciences · 2023Article
- Article
- Article
- Validating Immunomodulatory Responses of r-Pathogens (Basel, Switzerland) · 2022Article
- Structural insights into selective inhibition of leishmanial GDP-mannose pyrophosphorylase.Cell discovery · 2022Article
- Nanomedicine-based strategies to improve treatment of cutaneous leishmaniasis.Royal Society open science · 2022Article
- AKT Isoforms as a Target in Cancer and Immunotherapy.Current topics in microbiology and immunology · 2022Article
- Revisiting nature: a review of iridoids as a potential antileishmanial class.Phytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2022Review
- Modeling and simulation study to identify threonine synthase as possible drug target in Leishmania major.Molecular diversity · 2021Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Limited therapeutic options in visceral leishmaniasis (VL) make the treatment of this neglected disease very challenging. In addition to this, long treatment duration and toxic adverse effects make it even more difficult. With no effective vaccine available to date, treatment of VL is based only on chemotherapy. In the Indian subcontinent, a single dose of liposomal amphotericin B (L-AmB) and multidrug therapy (L-AmB + miltefosine, L-AmB + paromomycin [PM], or miltefosine + PM) are the treatments of choice for VL. In East Africa, however, combination therapy of pentavalent antimonials (Sb(v)) and PM remains the treatment of choice, and in the Mediterranean region and South America, L-AmB is the recommended drug. Fexinidazole and PA-824 are new promising drugs which have shown encouraging results in preclinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.